- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Why Real-World Data Is More Important than Ever
At this point of the evolving RWD landscape, we thought it appropriate to begin to broadly assess the use of real world data.
Our survey is open now.
While the impact and legacy of the very much on-going pandemic most acutely hits those infected, their families and friends, and the frontline healthcare providers, one clear legacy of this extraordinary moment will be how it helped show real world data is a critical component of the life sciences industry’s future.
There is now a daily public consumption of complex, evolving real world health data to an extraordinary degree. From the original goal of “flattening the curve” to rolling averages, and rates for testing, cases, hospitalizations, deaths, vaccinations and more, data inserts itself into the daily discourse up, down, and across society. At the same time, real world data continues to increasingly impact virtually every facet of what the life sciences industry does - from R&D strategy to commercialization – across therapeutic areas.
Again, your support of our survey is appreciated.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Approves AstraZeneca’s Calquence for Previously Untreated Mantle Cell Lymphoma
January 17th 2025Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously untreated mantle cell lymphoma.
